Having launched its first commercially-available product " Elute bidegradable, drug-loaded fibres for implantable medical textiles and nonwovens " in April last year, TissueGen ended 2013 by moving into a new manufacturing plant in Dallas, Texas, USA.
The company is now equipped with the on-site certified clean room and a dedicated extrusion room deemed essential as it focuses on the commercialisation of its proven technology for advanced drug delivery and sustained therapeutic release. It intends to apply for ISO 13485 certification this year.
Already have an account? Log In
Recommended
Most Popular
Latest Magazine
Features
Nonwovens News talks to Murat Dogru about the upcoming OUTLOOK conference
New line concepts and digital tools are helping nonwovens producers boost output, cut waste and ease labour pressures
New research is exploring the benefits of using PCM impregnated nonwovens for use in composite reinforcements for the construction sector
News
Lenzing to prioritise nonwovens as fibre business reshaped
Turkish yarn manufacturer to enter nonwovens market
Shaping the future of filtration at Filtrex
Other publications from MCL News & Media
